DE2413935C2 - - Google Patents

Info

Publication number
DE2413935C2
DE2413935C2 DE2413935A DE2413935A DE2413935C2 DE 2413935 C2 DE2413935 C2 DE 2413935C2 DE 2413935 A DE2413935 A DE 2413935A DE 2413935 A DE2413935 A DE 2413935A DE 2413935 C2 DE2413935 C2 DE 2413935C2
Authority
DE
Germany
Prior art keywords
pyrrolidone
general formula
phenyl
substituted phenyl
methoxyphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE2413935A
Other languages
German (de)
English (en)
Other versions
DE2413935A1 (de
Inventor
Ralph Dr. Schmiechen
Reinhard Dr. Horowski
Dieter Dr. Palenschat
Gert Paschelke
Helmut Dr. Wachtel
Wolfgang Dr. 1000 Berlin De Kehr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Priority to DE2413935A priority Critical patent/DE2413935A1/de
Priority to SU752111302A priority patent/SU649312A3/ru
Priority to YU632/75A priority patent/YU40258B/xx
Priority to DK110675A priority patent/DK139965C/da
Priority to DD184858A priority patent/DD119229A5/xx
Priority to CH345775A priority patent/CH621338A5/de
Priority to ES435750A priority patent/ES435750A1/es
Priority to HU75SCHE514A priority patent/HU174074B/hu
Priority to CS751860A priority patent/CS214738B2/cs
Priority to AT210975A priority patent/AT347931B/de
Priority to SE7503157A priority patent/SE402010B/xx
Priority to NL7503367A priority patent/NL7503367A/xx
Priority to FR7508701A priority patent/FR2264531B1/fr
Priority to JP50034220A priority patent/JPS6011028B2/ja
Priority to BE154536A priority patent/BE826923A/xx
Priority to AU79310/75A priority patent/AU496248B2/en
Priority to IE611/75A priority patent/IE40865B1/xx
Priority to IL46883A priority patent/IL46883A/xx
Priority to GB11686/75A priority patent/GB1498705A/en
Priority to CA222,720A priority patent/CA1069517A/en
Priority to US05/560,193 priority patent/US4012495A/en
Publication of DE2413935A1 publication Critical patent/DE2413935A1/de
Priority to US05/659,082 priority patent/US4193926A/en
Priority to AT367077A priority patent/AT347932B/de
Priority to CS802586A priority patent/CS214739B2/cs
Application granted granted Critical
Publication of DE2413935C2 publication Critical patent/DE2413935C2/de
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE2413935A 1974-03-20 1974-03-20 4-(polyalkoxy-phenyl)-2-pyrrolidone Granted DE2413935A1 (de)

Priority Applications (24)

Application Number Priority Date Filing Date Title
DE2413935A DE2413935A1 (de) 1974-03-20 1974-03-20 4-(polyalkoxy-phenyl)-2-pyrrolidone
SU752111302A SU649312A3 (ru) 1974-03-20 1975-03-10 Способ получени 4-(полиалкоксифенил)2-пирролидонов
YU632/75A YU40258B (en) 1974-03-20 1975-03-17 Process for obtaining new 4-(3-subt.-4-methoxy-phenyl)-2-pyrrolidones
DK110675A DK139965C (da) 1974-03-20 1975-03-18 Analogifremgangsmaade til fremstilling af 4-(4-metoksy-fenyl)-2-pyrrolidoner
DD184858A DD119229A5 (OSRAM) 1974-03-20 1975-03-18
CH345775A CH621338A5 (OSRAM) 1974-03-20 1975-03-18
ES435750A ES435750A1 (es) 1974-03-20 1975-03-18 Procedimiento para la preparacion de 4-(polialcoxi-fenil)-2-pirrolidonas.
CS751860A CS214738B2 (en) 1974-03-20 1975-03-19 Method for the production of racemic and optically active derivatives of 2-pyrrolidone
AT210975A AT347931B (de) 1974-03-20 1975-03-19 Verfahren zur herstellung von neuen 2- pyrrolidonderivaten
SE7503157A SE402010B (sv) 1974-03-20 1975-03-19 Sett att framstella derivat av 4-fenyl-2-pyrrolidon med terapeutiska egenskaper
HU75SCHE514A HU174074B (hu) 1974-03-20 1975-03-19 Sposob poluchenija 4-polialkoksi-fenil-2-pirrolidona
US05/560,193 US4012495A (en) 1974-03-20 1975-03-20 4-(Polyalkoxyphenyl)-2-pyrrolidones
NL7503367A NL7503367A (nl) 1974-03-20 1975-03-20 Werkwijze voor de bereiding van een geneesmiddel met neuro-psychotrope werking.
BE154536A BE826923A (fr) 1974-03-20 1975-03-20 (polyacoxy-phenyl)-4-pyrrolidinones-2 medicaments qui en contiennent
AU79310/75A AU496248B2 (en) 1974-03-20 1975-03-20 4 poly(substituted oxy phenyl 2-pyrrolidones
IE611/75A IE40865B1 (en) 1974-03-20 1975-03-20 4-(alkoxy-phenyl)-2-pyrrolidones,their preparation and use
IL46883A IL46883A (en) 1974-03-20 1975-03-20 4-(alkoxy and/or hydroxyphenyl)-pyrrolid-2-one or 2-thione derivatives, their preparation and pharmaceutical composiions containing the same
GB11686/75A GB1498705A (en) 1974-03-20 1975-03-20 4-(alkoxy-phenyl)-2-pyrrolidones their preparation and us
CA222,720A CA1069517A (en) 1974-03-20 1975-03-20 4-(polyalkoxy-phenyl)-2-pyrrolidone
FR7508701A FR2264531B1 (OSRAM) 1974-03-20 1975-03-20
JP50034220A JPS6011028B2 (ja) 1974-03-20 1975-03-20 新規４−（ポリアルコキシ−フエニル）−２−ピロリドンの製法
US05/659,082 US4193926A (en) 1974-03-20 1976-02-18 4-(Polyalkoxy phenyl)-2-pyrrolidones
AT367077A AT347932B (de) 1974-03-20 1977-05-23 Verfahren zur herstellung von neuen 2- pyrrolidonderivaten
CS802586A CS214739B2 (cs) 1974-03-20 1980-04-14 Způsob výroby racemických a opticky aktivních derivátů 2-pyrrolidonu

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2413935A DE2413935A1 (de) 1974-03-20 1974-03-20 4-(polyalkoxy-phenyl)-2-pyrrolidone

Publications (2)

Publication Number Publication Date
DE2413935A1 DE2413935A1 (de) 1975-10-16
DE2413935C2 true DE2413935C2 (OSRAM) 1988-05-26

Family

ID=5910915

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2413935A Granted DE2413935A1 (de) 1974-03-20 1974-03-20 4-(polyalkoxy-phenyl)-2-pyrrolidone

Country Status (20)

Country Link
US (1) US4012495A (OSRAM)
JP (1) JPS6011028B2 (OSRAM)
AT (1) AT347931B (OSRAM)
BE (1) BE826923A (OSRAM)
CA (1) CA1069517A (OSRAM)
CH (1) CH621338A5 (OSRAM)
CS (1) CS214738B2 (OSRAM)
DD (1) DD119229A5 (OSRAM)
DE (1) DE2413935A1 (OSRAM)
DK (1) DK139965C (OSRAM)
ES (1) ES435750A1 (OSRAM)
FR (1) FR2264531B1 (OSRAM)
GB (1) GB1498705A (OSRAM)
HU (1) HU174074B (OSRAM)
IE (1) IE40865B1 (OSRAM)
IL (1) IL46883A (OSRAM)
NL (1) NL7503367A (OSRAM)
SE (1) SE402010B (OSRAM)
SU (1) SU649312A3 (OSRAM)
YU (1) YU40258B (OSRAM)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193926A (en) 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
DE2541855A1 (de) * 1975-09-18 1977-03-31 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone ii
CU21107A3 (es) 1978-02-10 1988-02-01 Hoffmann La Roche Pyrrolidines derivatives
IL57266A (en) 1978-06-12 1982-12-31 Mundipharma Ag Production of pyrrolidin-2-ones and of 3-pyrrolin-2-ones
IT1131959B (it) * 1979-08-09 1986-06-25 Hoffmann La Roche Derivati pirrolidinici
GB2123288A (en) * 1982-07-16 1984-02-01 Wellcome Found Anti-thrombotic agent
US4548947A (en) * 1984-05-07 1985-10-22 Warner-Lambert Company 1-(Substituted-aryl)-dihydro-1H-pyrrolizine-3,5-[2H,6H-]diones and use for reversing amnesia
US4584313A (en) * 1984-05-07 1986-04-22 Warner-Lambert Company (Substituted-phenyl)-5-oxo-2-pyrrolidinepropanoic acids and esters thereof, and use for reversing electroconvulsive shock-induced amnesia
DE3438839A1 (de) * 1984-10-19 1986-04-24 Schering AG, 1000 Berlin und 4709 Bergkamen Pharmazeutische praeparate
US5783591A (en) * 1984-10-19 1998-07-21 Schering Aktiengesellschaft Administration of oxazolidinone and pyrolidinone compounds for the treatment of inflammation
HU215433B (hu) * 1986-04-29 2000-05-28 Pfizer Inc. Eljárás új 2-oxo-5-fenil-pirimidin-származékok előállítására
US5459145A (en) * 1988-01-19 1995-10-17 Pfizer Inc. Calcium independent camp phosphodiesterase inhibitor antidepressant
FI875101L (fi) * 1986-12-03 1988-06-04 Tanabe Seiyaku Co Laktamderivat och preparat innehaollande dessa.
US4971959A (en) * 1987-04-14 1990-11-20 Warner-Lambert Company Trisubstituted phenyl analogs having activity for congestive heart failure
US5274002A (en) * 1987-04-14 1993-12-28 Warner-Lambert Company Trisubstituted phenyl analogs having activity for congestive heart failure
US4960457A (en) * 1988-12-27 1990-10-02 Ici Americas Inc. Substituted 1,3-diphenyl pyrrolidones and their use as herbicides
DD295358A5 (de) * 1989-06-28 1991-10-31 �����@������������������k�� Verfahren zur racemattrennung von 4-aryl-2-oxo-pyrrolidin-3-carbonsaeure-estern
JP2578001B2 (ja) * 1989-12-11 1997-02-05 明治製菓株式会社 抗痴呆薬
DE3943385A1 (de) * 1989-12-27 1991-07-04 Schering Ag Mittel zur transdermalen applikation enthaltend rolipram
DD299058A5 (de) * 1990-01-31 1992-03-26 Arzneimittelwerk Dresden Gmbh,De Verfahren zur herstellung von n-acyl-4-phenyl-pyrrolidin-2-onen mit cerebroprotektiver wirkung
GB9009395D0 (en) * 1990-04-26 1990-06-20 Orion Yhtymae Oy Cyclic hydroxamic acids and their use
CA2088352A1 (en) * 1990-08-03 1992-02-04 Klaus M. Esser Tnf inhibitors
DE4032055A1 (de) * 1990-10-05 1992-04-09 Schering Ag Verfahren zur herstellung von optisch aktiven 4-aryl-2-pyrrolidinonen
US5547979A (en) * 1992-03-30 1996-08-20 Smithkline Beecham TNF inhibition
US5395935A (en) * 1992-05-08 1995-03-07 Pfizer Inc. Endo-bicyclo[2.2.1]heptan-2-ol and derived pharmaceutical agents
GB9212673D0 (en) * 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
US5622977A (en) * 1992-12-23 1997-04-22 Celltech Therapeutics Limited Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same
GB9226830D0 (en) * 1992-12-23 1993-02-17 Celltech Ltd Chemical compounds
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
US5477611A (en) * 1993-09-20 1995-12-26 Tessera, Inc. Method of forming interface between die and chip carrier
US5665754A (en) * 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
GB9326173D0 (en) * 1993-12-22 1994-02-23 Celltech Ltd Chemical compounds and process
WO1995017399A1 (en) * 1993-12-22 1995-06-29 Celltech Therapeutics Limited Trisubstituted phenyl derivatives, processes for their preparation and their use as phosphodiesterase (type iv) inhibitors
CA2143143A1 (en) * 1994-03-08 1995-09-09 Toshihiko Tanaka 3-phenylpyrrolidine derivatives
US5338739A (en) * 1994-03-10 1994-08-16 Hoechst-Roussel Pharmaceuticals Inc. (Pyrrolidinyl)phenyl carbamates, compositions and use
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
GB9412571D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412573D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412672D0 (en) * 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
US5922751A (en) 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
US5591776A (en) 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
US5665737B1 (en) * 1994-10-12 1999-02-16 Euro Celtique Sa Substituted benzoxazoles
US6025361A (en) 1994-12-13 2000-02-15 Euro-Celtique, S.A. Trisubstituted thioxanthines
DE69531506T2 (de) * 1994-12-13 2004-06-24 Euroceltique S.A. Arylthioxanthine
FI973277A7 (fi) * 1995-02-10 1997-08-08 Schering Ag Farmaseuttisia valmisteita TNF:n estämiseksi
US6268373B1 (en) 1995-06-07 2001-07-31 Euro-Celtique S.A. Trisubstituted thioxanthines
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
DE19540475A1 (de) * 1995-10-20 1997-04-24 Schering Ag Chirale Methylphenyloxazolidinone
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9526243D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
US6075016A (en) 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
US5864037A (en) 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
JP4017214B2 (ja) 1996-06-11 2007-12-05 興和創薬株式会社 ５−フェニル−３−ピリダジノン誘導体
DE69730980T2 (de) 1996-07-31 2006-02-23 Nikken Chemicals Co., Ltd. 6-phenyltetrahydro-1,3-oxazin-2-on derivate und medizinische zusammensetzungen, die sie enthalten
US6265402B1 (en) 1996-08-27 2001-07-24 Nikken Chemicals Co., Ltd. Use of 2-phenylmorpholin-5-one derivatives
US5744473A (en) * 1996-09-16 1998-04-28 Euro-Celtique, S.A. PDE IV inhibitors: "bis-compounds"
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
GB9625184D0 (en) * 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
US6057329A (en) * 1996-12-23 2000-05-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
GB9713087D0 (en) * 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
EP0994100B1 (en) 1997-06-24 2006-08-30 Nikken Chemicals Company, Limited 3-anilino-2-cycloalkenone derivates
CA2309350C (en) 1997-11-12 2007-04-03 Mitsubishi Chemical Corporation Purine derivatives and medicaments comprising the same as active ingredient
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
WO2000068231A1 (fr) * 1999-05-11 2000-11-16 Mitsubishi Chemical Corporation Dihydrate derive de purine, medicaments le contenant comme principe actif et intermediaire utilise dans sa preparation
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
ATE447952T1 (de) 1999-08-21 2009-11-15 Nycomed Gmbh Synergistische kombination von pumafentrine und salmeterol
GB9924862D0 (en) * 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
ATE347557T1 (de) * 2000-03-23 2006-12-15 Takeda Pharmaceutical Fluorisochinolinderivate, verfahren zu ihrer herstellung und ihre anwendung
CA2449118A1 (en) * 2001-05-29 2002-12-05 Schering Aktiengesellschaft Cdk inhibiting pyrimidines, production thereof and their use as medicaments
ATE517663T1 (de) * 2001-07-16 2011-08-15 Merck Patent Gmbh Photostabile organische sonnenschutzverbindungen mit antioxidationseigenschaften und daraus gewonnene zusammensetzungen
JP4514452B2 (ja) 2001-10-01 2010-07-28 ユニバーシティ オブ バージニア パテント ファウンデーション Ａ２ａアゴニスト活性を有する２−プロピルアデノシン・アナログおよびその組成物
CA2463469A1 (en) 2001-10-16 2003-04-24 Memory Pharmaceuticals Corporation 4-(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes
US20090170803A1 (en) * 2002-04-10 2009-07-02 Linden Joel M Adjunctive treatment of biological diseases
EP1541576A1 (en) * 2002-07-26 2005-06-15 Takeda Pharmaceutical Company Limited Furoisoquinoline derivative and use thereof
WO2004037784A2 (en) * 2002-10-21 2004-05-06 Irm Llc Pyrrolidones with anti-hiv activity
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
MXPA05010373A (es) 2003-04-01 2005-12-05 Applied Research Systems Inhibidores de fosfodiesterasas en infertilidad.
JP2006523710A (ja) * 2003-04-16 2006-10-19 メモリー・ファーマシューティカルズ・コーポレイション ホスホジエステラーゼ４インヒビター
US7226930B2 (en) * 2003-04-18 2007-06-05 Memory Pharmaceutical Corporation Phosphodiesterase 4 inhibitors
MXPA05011443A (es) * 2003-04-25 2006-05-31 Icos Corp Metodo de preparar un compuesto anular que tenga dos centros quirales adyancentes.
BRPI0511250A (pt) * 2004-05-17 2007-11-27 Otsuka Pharma Co Ltd composto de tiazol e uso deste
US7576069B2 (en) 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
WO2006023272A1 (en) 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
WO2006015357A2 (en) 2004-08-02 2006-02-09 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
JP2008516964A (ja) * 2004-10-15 2008-05-22 メモリー ファーマシューティカルス コーポレーション ホスホジエステラーゼ４阻害剤としてのピラゾール誘導体
CN101166737A (zh) * 2004-10-20 2008-04-23 记忆药物公司 磷酸二酯酶4抑制剂
WO2007120972A2 (en) * 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
JP5546451B2 (ja) 2007-06-04 2014-07-09 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸の障害、炎症、癌および他の障害の処置に有用なグアニル酸シクラーゼのアゴニスト
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US8058259B2 (en) 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
WO2010075086A2 (en) * 2008-12-15 2010-07-01 Auspex Pharmaceuticals, Inc. Pyrrolidinone inhibitors of pde-4
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EA201391254A1 (ru) 2011-03-01 2014-02-28 Синерджи Фармасьютикалз Инк. Способ получения агонистов гуанилатциклазы c
ES2395801B1 (es) 2011-06-23 2014-06-06 María Carmen PARDINA PALLEJÀ "pentoxifilina por vía transvaginal para el tratamiento de la infertilidad"
JP6499591B2 (ja) 2013-02-25 2019-04-10 シナジー ファーマシューティカルズ インコーポレイテッド 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
PL3004138T3 (pl) 2013-06-05 2024-07-29 Bausch Health Ireland Limited Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
EP3030252B1 (en) 2013-08-09 2018-11-07 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
JP2022533251A (ja) 2019-05-21 2022-07-21 アルデリックス， インコーポレイテッド 患者において血清リン酸塩を低下させるための組み合わせ

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1516776A (fr) 1966-07-21 1968-03-15 Rhone Poulenc Sa Nouveaux dérivés du pyrrole et leur préparation
GB1350582A (en) * 1970-07-24 1974-04-18 Ucb Sa Cerivatives of 2-pyrrolidinone

Also Published As

Publication number Publication date
SE7503157L (sv) 1975-11-28
DD119229A5 (OSRAM) 1976-04-12
HU174074B (hu) 1979-10-28
SU649312A3 (ru) 1979-02-25
CH621338A5 (OSRAM) 1981-01-30
DK110675A (OSRAM) 1975-09-21
US4012495A (en) 1977-03-15
DK139965C (da) 1979-10-29
DK139965B (da) 1979-05-28
IE40865B1 (en) 1979-08-29
FR2264531A1 (OSRAM) 1975-10-17
FR2264531B1 (OSRAM) 1978-07-28
SE402010B (sv) 1978-06-12
IL46883A (en) 1979-09-30
DE2413935A1 (de) 1975-10-16
JPS6011028B2 (ja) 1985-03-22
IE40865L (en) 1975-09-20
YU63275A (en) 1982-06-30
GB1498705A (en) 1978-01-25
AT347931B (de) 1979-01-25
BE826923A (fr) 1975-09-22
ATA210975A (de) 1978-06-15
JPS50157360A (OSRAM) 1975-12-19
CS214738B2 (en) 1982-05-28
YU40258B (en) 1985-10-31
NL7503367A (nl) 1975-09-23
CA1069517A (en) 1980-01-08
ES435750A1 (es) 1976-12-16
AU7931075A (en) 1976-09-23
IL46883A0 (en) 1975-05-22

Similar Documents

Publication Publication Date Title
DE2413935C2 (OSRAM)
DE69709938T2 (de) N-benzylpiperidin- und tetrahydropyridin-derivate
DE1668055C3 (OSRAM)
CH621115A5 (OSRAM)
DE2108438A1 (de) Benzylimidazolidinone
DE2541855A1 (de) 4-(polyalkoxy-phenyl)-2-pyrrolidone ii
DE2542881B2 (de) Razemische oder optisch aktive Benzylalkoholderivate, Verfahren zu ihrer Herstellung und sie enthaltende therapeutische Zubereitung
DE2337340C2 (de) 6-Chlor-α-methylcarbazol-2-essigsäure und deren Salze
DE69101141T2 (de) Neue Guanidinderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen.
CH646426A5 (en) Process for the preparation of hydantoin derivatives
DE2413102A1 (de) Verfahren zur herstellung von 1-(3,5dihydroxyphenyl)-1-hydroxy-2- eckige klammer auf 1-methyl-2-(4-hydroxyphenyl)-aethyl eckige klammer zu -amino-aethan
DE1595920B2 (de) 4-(co-Piperazinoalkyl)-pyrazole, ihre Salze und Verfahren zu ihrer Herstellung
DE2044172A1 (de) Neue Pyrroldenvate, ein Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimittelzubereitungen
DE2503751C2 (de) (L)-1-Phenoxy-3-isopropylamino-2-propanol und dessen Salze, Verfahren zur Herstellung und Verwendung
DE1695193A1 (de) Verfahren zur Herstellung von Chinazolin-Derivaten
DE2818290A1 (de) Neue naphthyridine
DE2313625C2 (de) α-(Aminoalkyl)-4-hydroxy-3-(methylsulfonylmethyl)-benzylalkohole, ihre Salze, Verfahren zu ihrer Herstellung und ihre Verwendung
DE1768366C3 (de) 3-Hydroxy-alpha-(l-aminoäthyl)benzylalkohol-derivate und diese enthaltende Arzneimittel
DE1643860A1 (de) Tricyclische Phenoxycarbonsaeuren
DE900938C (de) Verfahren zur Herstellung von 1-(o-Oxyphenyl)-1-oxy-2-aralkylamino-propanen
DE3003323A1 (de) 4-amino-2-piperidinochinazolin-derivate, verfahren zu ihrer herstellung und solche derivate enthaltende arzneimittel
DE1493961A1 (de) Verfahren zur Herstellung von substituierten 1-Hydroxy-2-alkylamino-1-phenylalkanen
DE1169450B (de) Verfahren zur Herstellung von Indolinderivaten und deren Salzen
DE2328758C2 (de) 4,4-Diphenyl-2-methyl-2-hydroxybutylamine und diese enthaltende therapeutische Zubereitungen
DE2229894A1 (de) Äthanolaminderivate, ihre Salze, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneipräparate

Legal Events

Date Code Title Description
OD Request for examination
AG Has addition no.

Ref country code: DE

Ref document number: 2541855

Format of ref document f/p: P

D2 Grant after examination
8364 No opposition during term of opposition